Trial Profile
The use of dendritic cell/tumor hybridomas as a novel tumor vaccine in patients with advance melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Mar 2017
Price :
$35
*
At a glance
- Drugs Melanoma vaccine (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2017 Status changed to completed.
- 19 Mar 2008 New trial record.